尿渗透压、托伐普坦反应与常染色体显性多囊肾病结局:TEMPO 3:4 试验结果
本研究基于 TEMPO 3:4 随机安慰剂对照试验,分析常染色体显性多囊肾病(ADPKD)患者基线尿渗透压(Uosm)的决定因素及其与托伐普坦反应和结局的关系。托伐普坦持续降低 Uosm 200-300 mOsm/kg,Uosm 降幅更大的患者临床进展事件显著减少且肾功能下降更慢。
要点
- 基线 Uosm 较低独立关联女性、高血压、较低 eGFR、较高 TKV 和较高年龄。
- 托伐普坦在 36 个月内持续降低 Uosm 200-300 mOsm/kg。
- Uosm 抑制幅度更大的托伐普坦组患者肾功能下降更慢、临床进展事件更少。
核心结论
- ADPKD 患者基线 Uosm 反映年龄、肾功能和 TKV,基线 Uosm、eGFR 和 TKV 影响托伐普坦对 Uosm 的效果。
- Uosm 抑制幅度更大者肾脏获益最大,即基线 eGFR 更好的患者。
- 结果支持血管加压素 V2 受体信号与 ADPKD 进展之间的关联。
研究设计与样本
- TEMPO 3:4 试验的事后分析,该试验为为期 3 年的随机、安慰剂对照试验,纳入成人 ADPKD 患者。
- 研究分析基线 Uosm 的决定因素、其作为 ADPKD 严重程度标志物的价值、影响托伐普坦反应的因素以及 Uosm 变化与关键试验终点的关联。
主要发现
- 基线时,较低 Uosm 独立关联女性、高血压、较低 eGFR、较高 TKV 和较高年龄。
- 托伐普坦在 36 个月内持续降低 Uosm 200-300 mOsm/kg。
- Uosm 对托伐普坦的反应取决于基线 eGFR 和 Uosm。
- Uosm 变化更大的受试者临床进展事件显著减少。
- 接受托伐普坦的受试者中,Uosm 抑制更大者肾功能下降更慢。
关键数值与推荐
- 托伐普坦持续降低 Uosm 200-300 mOsm/kg(36 个月)。
- Uosm 对托伐普坦的反应取决于基线 eGFR 和 Uosm。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The vasopressin-cAMP-osmolality axis is abnormal in autosomal dominant polycystic kidney disease (ADPKD). In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 Trial, a 3-year randomized, placebo-controlled trial in adults, the vasopressin V2 receptor antagonist tolvaptan slowed ADPKD progression in patients with preserved GFR. Here, we investigated the determinants of baseline urine osmolality (Uosm) and its value as a severity marker of ADPKD, the factors influencing the response to tolvaptan, and whether change in Uosm associated with key trial end points. At baseline, lower Uosm independently associated with female sex, presence of hypertension, lower eGFR, higher total kidney volume (TKV), and higher age. Tolvaptan consistently reduced Uosm by 200-300 mOsm/kg over 36 months. The Uosm response to tolvaptan depended on baseline eGFR and Uosm. Subjects with greater change in Uosm experienced a significant reduction in clinical progression events. Among subjects receiving tolvaptan, those with a greater suppression of Uosm had slower renal function decline. Assessment at follow-up, off medication, revealed a significant decrease in Uosm in both placebo and treated groups. Tolvaptan significantly increased plasma osmolality, which returned to baseline at follow-up. In conclusion, baseline Uosm in ADPKD reflects age, renal function, and TKV, and baseline Uosm, eGFR, and TKV influence the effect of tolvaptan on Uosm. The greatest renal benefit occurred in subjects achieving greater suppression of Uosm, that is, those with better eGFR at baseline. These results support the link between vasopressin V2 receptor signaling and ADPKD progression.
引用
- Devuyst O, Chapman AB, Gansevoort RT, et al. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. J Am Soc Nephrol. 2016. PMID: 27920153. doi:10.1681/ASN.2016040448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。